Translate

Τρίτη 26 Οκτωβρίου 2021

Ponatinib-induced eruptive nevi and melanocytic proliferation

xlomafota13 shared this article with you from Inoreader

SocialThumb.00008390.DC.jpeg

Ponatinib, an oral third-generation tyrosine kinase inhibitor, is indicated for the treatment of imatinib-resistant leukemia. We experienced a case of ponatinib-induced eruptive nevi, and the biologic effects of ponatinib on melanocytes were investigated. Treatment with ponatinib significantly increased the proliferat ion of normal human melanocyte or melanoma cells through the upregulation of the extracellular signal-regulated kinase and protein kinase B signaling pathways. The downstream molecules of cyclin B1 and D1 were significantly increased in ponatinib-treated melanocytes. These results demonstrate the capacity of ponatinib to induce the proliferation and tumorigenesis of melanocytes. Received 23 July 2021 Accepted 21 September 2021 Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.melanomaresearch.com. Correspondence to Hee Young Kang, MD, PhD, Department of Dermatology, Ajou University School of Medicine, Ajou University Hospital, 164, World Cup-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16499, South Korea, Tel: +82 31 219 5190; fax: +82 31 219 5189; e-mail: hykang@ajou.ac.kr Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
View on the web

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου

Translate